A federal judge in Trenton has dismissed the last remaining 570 cases in multidistrict litigation over Merck’s osteoporosis drug Fosamax, but the cases could be reinstated if plaintiffs win an appeal currently pending before the U.S. Court of Appeals for the Third Circuit.
U.S. District Judge Freda Wolfson of the District of New Jersey dismissed the remaining cases after finding they were based on claims that a pre-2011 warning label on the drug failed to sufficiently warn users that the drug could cause femur fractures.
